-
Carbon Monoxide Signaling: Examining Its Engagement with Various Molecular Targets in the Context of Binding Affinity, Concentration, and Biologic Response Pharmacol. Rev. (IF 25.468) Pub Date : 2022-07-01 Zhengnan Yuan, Ladie Kimberly De La Cruz, Xiaoxiao Yang, Binghe Wang, Qiang Ma
Carbon monoxide (CO) has been firmly established as an endogenous signaling molecule with a variety of pathophysiological and pharmacological functions, including immunomodulation, organ protection, and circadian clock regulation, among many others. In terms of its molecular mechanism(s) of action, CO is known to bind to a large number of hemoproteins with at least 25 identified targets, including
-
ATP and Adenosine Metabolism in Cancer: Exploitation for Therapeutic Gain Pharmacol. Rev. (IF 25.468) Pub Date : 2022-07-01 Gennady G. Yegutkin, Detlev Boison, Stephen Alexander
Adenosine is an evolutionary ancient metabolic regulator linking energy state to physiologic processes, including immunomodulation and cell proliferation. Tumors create an adenosine-rich immunosuppressive microenvironment through the increased release of ATP from dying and stressed cells and its ectoenzymatic conversion into adenosine. Therefore, the adenosine pathway becomes an important therapeutic
-
Quantitative Proteomics in Translational Absorption, Distribution, Metabolism, and Excretion and Precision Medicine Pharmacol. Rev. (IF 25.468) Pub Date : 2022-07-01 Deepak Ahire, Laken Kruger, Sheena Sharma, Vijaya Saradhi Mettu, Abdul Basit, Bhagwat Prasad, Charles France
A reliable translation of in vitro and preclinical data on drug absorption, distribution, metabolism, and excretion (ADME) to humans is important for safe and effective drug development. Precision medicine that is expected to provide the right clinical dose for the right patient at the right time requires a comprehensive understanding of population factors affecting drug disposition and response. Characterization
-
Matrix Metalloproteinases: From Molecular Mechanisms to Physiology, Pathophysiology, and Pharmacology Pharmacol. Rev. (IF 25.468) Pub Date : 2022-07-01 Luiz G.N. de Almeida, Hayley Thode, Yekta Eslambolchi, Sameeksha Chopra, Daniel Young, Sean Gill, Laurent Devel, Antoine Dufour, Gunnar Schulte
-
New Technologies Bloom Together for Bettering Cancer Drug Conjugates Pharmacol. Rev. (IF 25.468) Pub Date : 2022-07-01 Yiming Jin, Shahab Edalatian Zakeri, Raman Bahal, Andrew J. Wiemer, Eric Barker
-
Mass Spectrometry Approaches Empowering Neuropeptide Discovery and Therapeutics Pharmacol. Rev. (IF 25.468) Pub Date : 2022-07-01 Krishna D. B. Anapindi, Elena V. Romanova, James W. Checco, Jonathan V. Sweedler, Vivian Hook
-
Allosteric Modulators of Metabotropic Glutamate Receptors as Novel Therapeutics for Neuropsychiatric Disease Pharmacol. Rev. (IF 25.468) Pub Date : 2022-07-01 Deborah J. Luessen, P. Jeffrey Conn, Lynette Daws
Metabotropic glutamate (mGlu) receptors, a family of G-protein-coupled receptors, have been identified as novel therapeutic targets based on extensive research supporting their diverse contributions to cell signaling and physiology throughout the nervous system and important roles in regulating complex behaviors, such as cognition, reward, and movement. Thus, targeting mGlu receptors may be a promising
-
Cathepsin B Gene Knockout Improves Behavioral Deficits and Reduces Pathology in Models of Neurologic Disorders Pharmacol. Rev. (IF 25.468) Pub Date : 2022-07-01 Gregory Hook, Thomas Reinheckel, Junjun Ni, Zhou Wu, Mark Kindy, Christoph Peters, Vivian Hook, Eric Barker
-
The Nitrogen Mustards Pharmacol. Rev. (IF 25.468) Pub Date : 2022-07-01 Martin S. Highley, Bart Landuyt, Hans Prenen, Peter G. Harper, Ernst A. De Bruijn, Michael Gottesman
-
Acylcarnitines: Nomenclature, Biomarkers, Therapeutic Potential, Drug Targets, and Clinical Trials Pharmacol. Rev. (IF 25.468) Pub Date : 2022-07-01 Maija Dambrova, Marina Makrecka-Kuka, Janis Kuka, Reinis Vilskersts, Didi Nordberg, Misty M. Attwood, Stefan Smesny, Zumrut Duygu Sen, An Chi Guo, Eponine Oler, Siyang Tian, Jiamin Zheng, David S. Wishart, Edgars Liepinsh, Helgi B. Schiöth, Jukka Hakkola
-
Kidney Angiotensin in Cardiovascular Disease: Formation and Drug Targeting Pharmacol. Rev. (IF 25.468) Pub Date : 2022-07-01 Hui Lin, Frank Geurts, Luise Hassler, Daniel Batlle, Katrina M. Mirabito Colafella, Kate M. Denton, Jia L. Zhuo, Xiao C. Li, Nirupama Ramkumar, Masahiro Koizumi, Taiji Matsusaka, Akira Nishiyama, Martin J. Hoogduijn, Ewout J. Hoorn, A.H. Jan Danser, Rhian Touyz
-
Therapeutic Opportunities and Delivery Strategies for Brain Revascularization in Stroke, Neurodegeneration, and Aging Pharmacol. Rev. (IF 25.468) Pub Date : 2022-03-17 Gallego, I., Villate-Beitia, I., Saenz-del-Burgo, L., Puras, G., Pedraz, J. L.
Central nervous system (CNS) diseases, especially acute ischemic events and neurodegenerative disorders, constitute a public health problem with no effective treatments to allow a persistent solution. Failed therapies targeting neuronal recovery have revealed the multifactorial and intricate pathophysiology underlying such CNS disorders as ischemic stroke, Alzheimeŕs disease, amyotrophic lateral sclerosis
-
Post-Traumatic Epilepsy and Comorbidities: Advanced Models, Molecular Mechanisms, Biomarkers, and Novel Therapeutic Interventions Pharmacol. Rev. (IF 25.468) Pub Date : 2022-04-01 Victoria M. Golub, Doodipala Samba Reddy, Charles France
-
Targeting the Adaptive Immune System in Depression: Focus on T Helper 17 Cells Pharmacol. Rev. (IF 25.468) Pub Date : 2022-04-01 Eléonore Beurel, Eva M. Medina-Rodriguez, Richard S. Jope, Robert Dantzer
There is a vital need to understand mechanisms contributing to susceptibility to depression to improve treatments for the 11% of Americans who currently suffer from this debilitating disease. The adaptive immune system, comprising T and B cells, has emerged as a potential contributor to depression, as demonstrated in the context of lymphopenic mice. Overall, patients with depression have reduced circulating
-
International Union of Basic and Clinical Pharmacology. CXII: Adenosine Receptors: A Further Update Pharmacol. Rev. (IF 25.468) Pub Date : 2022-04-01 Adriaan P. IJzerman, Kenneth A. Jacobson, Christa E. Müller, Bruce N. Cronstein, Rodrigo A. Cunha, Eliot Ohlstein
Our previous International Union of Basic and Clinical Pharmacology report on the nomenclature and classification of adenosine receptors (2011) contained a number of emerging developments with respect to this G protein-coupled receptor subfamily, including protein structure, protein oligomerization, protein diversity, and allosteric modulation by small molecules. Since then, a wealth of new data and
-
Therapeutic Opportunities and Delivery Strategies for Brain Revascularization in Stroke, Neurodegeneration, and Aging Pharmacol. Rev. (IF 25.468) Pub Date : 2022-03-17 Idoia Gallego,Ilia Villate-Beitia,Laura Saenz-del-Burgo,Gustavo Puras,José Luis Pedraz
-
Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines Pharmacol. Rev. (IF 25.468) Pub Date : 2022-01-01 Simone Pecetta, Sven Kratochvil, Yu Kato, Kumaran Vadivelu, Rino Rappuoli, Qiang Ma
-
Neurobiological Mechanisms of Nicotine Reward and Aversion Pharmacol. Rev. (IF 25.468) Pub Date : 2022-01-01 Lauren Wills, Jessica L. Ables, Kevin M. Braunscheidel, Stephanie P.B. Caligiuri, Karim S. Elayouby, Clementine Fillinger, Masago Ishikawa, Janna K. Moen, Paul J. Kenny, Charles France
-
α6-Containing GABAAReceptors: Functional Roles and Therapeutic Potentials Pharmacol. Rev. (IF 25.468) Pub Date : 2022-01-01 Werner Sieghart, Lih-Chu Chiou, Margot Ernst, Jure Fabjan, Miroslav M. Savić, Ming Tatt Lee, Charles France
-
Therapeutics in the Pipeline Targetingα-Synuclein for Parkinson's Disease Pharmacol. Rev. (IF 25.468) Pub Date : 2022-01-01 Hilary Grosso Jasutkar, Stephanie E. Oh, M. Maral Mouradian, Eric Barker
-
Organotypic and Microphysiological Human Tissue Models for Drug Discovery and Development—Current State-of-the-Art and Future Perspectives Pharmacol. Rev. (IF 25.468) Pub Date : 2022-01-01 Sonia Youhanna, Aurino M. Kemas, Lena Preiss, Yitian Zhou, Joanne X. Shen, Selgin D. Cakal, Francesco S. Paqualini, Sravan K. Goparaju, Reza Zandi Shafagh, Johan Ulrik Lind, Carl M. Sellgren, Volker M. Lauschke, David R. Sibley
-
Sex Differences in Opioid and Psychostimulant Craving and Relapse: A Critical Review Pharmacol. Rev. (IF 25.468) Pub Date : 2022-01-01 Céline Nicolas, Natalie E. Zlebnik, Mehdi Farokhnia, Lorenzo Leggio, Satoshi Ikemoto, Yavin Shaham, Michael Nader
A widely held dogma in the preclinical addiction field is that females are more vulnerable than males to drug craving and relapse. Here, we first review clinical studies on sex differences in psychostimulant and opioid craving and relapse. Next, we review preclinical studies on sex differences in psychostimulant and opioid reinstatement of drug seeking after extinction of drug self-administration,
-
Inhaled Medicines: Past, Present, and Future Pharmacol. Rev. (IF 25.468) Pub Date : 2022-01-01 Sandra Anderson, Paul Atkins, Per Bäckman, David Cipolla, Andrew Clark, Evangelia Daviskas, Bernd Disse, Plamena Entcheva-Dimitrov, Rick Fuller, Igor Gonda, Hans Lundbäck, Bo Olsson, Jeffry Weers, Clive Page
-
The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein Pharmacol. Rev. (IF 25.468) Pub Date : 2022-01-01 Lauren M. Lucas, Vipasha Dwivedi, Jared I. Senfeld, Richard L. Cullum, Christopher P. Mill, J. Tyler Piazza, Ianthe N. Bryant, Laura J. Cook, S. Tyler Miller, James H. Lott, Connor M. Kelley, Elizabeth L. Knerr, Jessica A. Markham, David P. Kaufmann, Megan A. Jacobi, Jianzhong Shen, David J. Riese, Eric Barker
-
Targeting Systemic Innate Immune Cells as a Therapeutic Avenue for Alzheimer Disease Pharmacol. Rev. (IF 25.468) Pub Date : 2022-01-01 Vincent Pons, Serge Rivest, Robert Dantzer
Alzheimer disease (AD) is the first progressive neurodegenerative disease worldwide, and the disease is characterized by an accumulation of amyloid in the brain and neurovasculature that triggers cognitive decline and neuroinflammation. The innate immune system has a preponderant role in AD. The last decade, scientists focused their efforts on therapies aiming to modulate innate immunity. The latter
-
A Commitment to Excellence from the New Editor. Pharmacol. Rev. (IF 25.468) Pub Date : 2022-01-01 Lynette C Daws
-
Inhaledβ2 Adrenergic Agonists and Other cAMP-Elevating Agents: Therapeutics for Alveolar Injury and Acute Respiratory Disease Syndrome? Pharmacol. Rev. (IF 25.468) Pub Date : 2021-10-01 Krishna Sriram, Michael B. Insel, Paul A. Insel, Clive Page
Inhaled long-acting β-adrenergic agonists (LABAs) and short-acting β-adrenergic agonists are approved for the treatment of obstructive lung disease via actions mediated by β2 adrenergic receptors (β2-ARs) that increase cellular cAMP synthesis. This review discusses the potential of β2-AR agonists, in particular LABAs, for the treatment of acute respiratory distress syndrome (ARDS). We emphasize ARDS
-
Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels Pharmacol. Rev. (IF 25.468) Pub Date : 2021-11-09 Hansen, K. B., Wollmuth, L. P., Bowie, D., Furukawa, H., Menniti, F. S., Sobolevsky, A. I., Swanson, G. T., Swanger, S. A., Greger, I. H., Nakagawa, T., McBain, C. J., Jayaraman, V., Low, C.-M., DellAcqua, M. L., Diamond, J. S., Camp, C. R., Perszyk, R. E., Yuan, H., Traynelis, S. F.
Many physiologic effects of l-glutamate, the major excitatory neurotransmitter in the mammalian central nervous system, are mediated via signaling by ionotropic glutamate receptors (iGluRs). These ligand-gated ion channels are critical to brain function and are centrally implicated in numerous psychiatric and neurologic disorders. There are different classes of iGluRs with a variety of receptor subtypes
-
Regulation of Mitogen-Activated Protein Kinase Signaling Pathways by the Ubiquitin-Proteasome System and Its Pharmacological Potential Pharmacol. Rev. (IF 25.468) Pub Date : 2021-10-01 Simon Mathien, Chloé Tesnière, Sylvain Meloche, Michael Gottesman
-
Nonantimicrobial Actions of Macrolides: Overview and Perspectives for Future Development Pharmacol. Rev. (IF 25.468) Pub Date : 2021-10-01 Jennifer A. Kricker, Clive P. Page, Fridrik Runar Gardarsson, Olafur Baldursson, Thorarinn Gudjonsson, Michael J. Parnham, Eric Barker
-
Pharmacological Modulation of Immune Responses by Nutritional Components Pharmacol. Rev. (IF 25.468) Pub Date : 2021-10-01 Marthe T. van Daal, Gert Folkerts, Johan Garssen, Saskia Braber
-
Gαs–Protein Kinase A (PKA) Pathway Signalopathies: The Emerging Genetic Landscape and Therapeutic Potential of Human Diseases Driven by Aberrant Gαs-PKA Signaling Pharmacol. Rev. (IF 25.468) Pub Date : 2021-10-01 Dana J. Ramms, Francesco Raimondi, Nadia Arang, Friedrich W. Herberg, Susan S. Taylor, J. Silvio Gutkind, Gunnar Schulte
-
L-Type Calcium Channel Blockers: A Potential Novel Therapeutic Approach to Drug Dependence Pharmacol. Rev. (IF 25.468) Pub Date : 2021-10-01 Hilary J. Little, Stephen Alexander
This review describes interactions between compounds, primarily dihydropyridines, that block L-type calcium channels and drugs that cause dependence, and the potential importance of these interactions. The main dependence-inducing drugs covered are alcohol, psychostimulants, opioids, and nicotine. In preclinical studies, L-type calcium channel blockers prevent or reduce important components of dependence
-
Analgesic Potential of Terpenes Derived fromCannabis sativa Pharmacol. Rev. (IF 25.468) Pub Date : 2021-10-01 Erika Liktor-Busa, Attila Keresztes, Justin LaVigne, John M. Streicher, Tally M. Largent-Milnes
-
Parkinson Disease: Translating Insights from Molecular Mechanisms to Neuroprotection Pharmacol. Rev. (IF 25.468) Pub Date : 2021-10-01 Sheila K. Pirooznia, Liana S. Rosenthal, Valina L. Dawson, Ted M. Dawson, Eric Barker
-
Brain Cancer Drug Discovery: Clinical Trials, Drug Classes, Targets, and Combinatorial Therapies Pharmacol. Rev. (IF 25.468) Pub Date : 2021-10-01 Aleksandr V. Sokolov, Samira A. Dostdar, Misty M. Attwood, Aleksandra A. Krasilnikova, Anastasia A. Ilina, Amina Sh. Nabieva, Anna A. Lisitsyna, Vladimir N. Chubarev, Vadim V. Tarasov, Helgi B. Schiöth, Michael Gottesman
-
Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels Pharmacol. Rev. (IF 25.468) Pub Date : 2021-10-01 Kasper B. Hansen,Lonnie P. Wollmuth,Derek Bowie,Hiro Furukawa,Frank S. Menniti,Alexander I. Sobolevsky,Geoffrey T. Swanson,Sharon A. Swanger,Ingo H. Greger,Terunaga Nakagawa,Chris J. McBain,Vasanthi Jayaraman,Chian-Ming Low,Mark L. Dell’Acqua,Jeffrey S. Diamond,Chad R. Camp,Riley E. Perszyk,Hongjie Yuan,Stephen F. Traynelis
Many physiologic effects of l-glutamate, the major excitatory neurotransmitter in the mammalian central nervous system, are mediated via signaling by ionotropic glutamate receptors (iGluRs). These ligand-gated ion channels are critical to brain function and are centrally implicated in numerous psychiatric and neurologic disorders. There are different classes of iGluRs with a variety of receptor subtypes
-
Structure-Based Virtual Screening for Ligands of G Protein–Coupled Receptors: What Can Molecular Docking Do for You? Pharmacol. Rev. (IF 25.468) Pub Date : 2021-10-01 Flavio Ballante, Albert J Kooistra, Stefanie Kampen, Chris de Graaf, Jens Carlsson, GUNNAR SCHULTE
-
Aldo-Keto Reductases and Cancer Drug Resistance Pharmacol. Rev. (IF 25.468) Pub Date : 2021-07-01 Trevor M. Penning, Sravan Jonnalagadda, Paul C. Trippier, Tea Lanišnik Rižner, Michael Gottesman
-
Therapeutic Targeting ofα7 Nicotinic Acetylcholine Receptors Pharmacol. Rev. (IF 25.468) Pub Date : 2021-07-01 Roger L. Papke, Nicole A. Horenstein, Habibeh Khoshbouei
The α7-type nicotinic acetylcholine receptor is one of the most unique and interesting of all the members of the cys-loop superfamily of ligand-gated ion channels. Since it was first identified initially as a binding site for α-bungarotoxin in mammalian brain and later as a functional homomeric receptor with relatively high calcium permeability, it has been pursued as a potential therapeutic target
-
Aiding and Abetting Anhedonia: Impact of Inflammation on the Brain and Pharmacological Implications Pharmacol. Rev. (IF 25.468) Pub Date : 2021-07-01 Michael J. Lucido, Mandy Bekhbat, David R. Goldsmith, Michael T. Treadway, Ebrahim Haroon, Jennifer C. Felger, Andrew H. Miller, Robert Dantzer
-
Animal Models of Drug Relapse and Craving after Voluntary Abstinence: A Review Pharmacol. Rev. (IF 25.468) Pub Date : 2021-07-01 Ida Fredriksson, Marco Venniro, David J. Reiner, Jonathan J. Chow, Jennifer M. Bossert, Yavin Shaham, Michael Nader
Relapse to drug use during abstinence is a defining feature of addiction. During the last several decades, this clinical scenario has been studied at the preclinical level using classic relapse/reinstatement models in which drug seeking is assessed after experimenter-imposed home-cage forced abstinence or extinction of the drug-reinforced responding in the self-administration chambers. To date, however
-
The Molecular Biology of Phosphodiesterase 4 Enzymes as Pharmacological Targets: An Interplay of Isoforms, Conformational States, and Inhibitors Pharmacol. Rev. (IF 25.468) Pub Date : 2021-07-01 Dean Paes, Melissa Schepers, Ben Rombaut, Daniel van den Hove, Tim Vanmierlo, Jos Prickaerts, Martin Michel
The phosphodiesterase 4 (PDE4) enzyme family plays a pivotal role in regulating levels of the second messenger cAMP. Consequently, PDE4 inhibitors have been investigated as a therapeutic strategy to enhance cAMP signaling in a broad range of diseases, including several types of cancers, as well as in various neurologic, dermatological, and inflammatory diseases. Despite their widespread therapeutic
-
New Aspects of Diabetes Research and Therapeutic Development Pharmacol. Rev. (IF 25.468) Pub Date : 2021-07-01 Leslie S. Satin, Scott A. Soleimanpour, Emily M. Walker, Lori Isom
Both type 1 and type 2 diabetes mellitus are advancing at exponential rates, placing significant burdens on health care networks worldwide. Although traditional pharmacologic therapies such as insulin and oral antidiabetic stalwarts like metformin and the sulfonylureas continue to be used, newer drugs are now on the market targeting novel blood glucose–lowering pathways. Furthermore, exciting new developments
-
Pharmacological Inhibition of the Nod-Like Receptor Family Pyrin Domain Containing 3 Inflammasome with MCC950 Pharmacol. Rev. (IF 25.468) Pub Date : 2021-07-01 Sarah E. Corcoran, Reena Halai, Matthew A. Cooper, Clive Page
-
Endothelial Dysfunction in Atherosclerotic Cardiovascular Diseases and Beyond: From Mechanism to Pharmacotherapies Pharmacol. Rev. (IF 25.468) Pub Date : 2021-07-01 Suowen Xu, Iqra Ilyas, Peter J. Little, Hong Li, Danielle Kamato, Xueying Zheng, Sihui Luo, Zhuoming Li, Peiqing Liu, Jihong Han, Ian C. Harding, Eno E. Ebong, Scott J. Cameron, Alastair G. Stewart, Jianping Weng, Qiang Ma
-
Unlocking G-Quadruplexes as Antiviral Targets Pharmacol. Rev. (IF 25.468) Pub Date : 2021-07-01 Ardavan Abiri, Marc Lavigne, Masoud Rezaei, Sanaz Nikzad, Peyman Zare, Jean-Louis Mergny, Hamid-Reza Rahimi, Rhian Touyz
-
The Emerging Role of the Innate Immune Response in Idiosyncratic Drug Reactions Pharmacol. Rev. (IF 25.468) Pub Date : 2021-07-01 Samantha Christine Sernoskie, Alison Jee, Jack Paul Uetrecht, Eric Barker
-
Correction to "Cognitive Effects of MDMA in Laboratory Animals: A Systematic Review Focusing on Dose". Pharmacol. Rev. (IF 25.468) Pub Date : 2021-04-01
-
Correction to "Sex- and Gender-Based Pharmacological Response to Drugs". Pharmacol. Rev. (IF 25.468) Pub Date : 2021-04-01
-
Correction to "Sex- and Gender-Based Pharmacological Response to Drugs". Pharmacol. Rev. (IF 25.468) Pub Date : 2021-04-01
-
Modeling Pharmacokinetic Natural Product–Drug Interactions for Decision-Making: A NaPDI Center Recommended Approach Pharmacol. Rev. (IF 25.468) Pub Date : 2021-04-01 Emily J. Cox, Dan-Dan Tian, John D. Clarke, Allan E. Rettie, Jashvant D. Unadkat, Kenneth E. Thummel, Jeannine S. McCune, Mary F. Paine, Hyunyoung Jeong
The popularity of botanical and other purported medicinal natural products (NPs) continues to grow, especially among patients with chronic illnesses and patients managed on complex prescription drug regimens. With few exceptions, the risk of a given NP to precipitate a clinically significant pharmacokinetic NP-drug interaction (NPDI) remains understudied or unknown. Application of static or dynamic
-
Viral G Protein–Coupled Receptors: Attractive Targets for Herpesvirus-Associated Diseases Pharmacol. Rev. (IF 25.468) Pub Date : 2021-04-01 Timo W. M. De Groof, Elizabeth G. Elder, Marco Siderius, Raimond Heukers, John H. Sinclair, Martine J. Smit, Gunnar Schulte
-
Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics Pharmacol. Rev. (IF 25.468) Pub Date : 2021-04-01 Peter Garred, Andrea J. Tenner, Tom E. Mollnes, Finn Olav Levy
-
Hydroxynorketamines: Pharmacology and Potential Therapeutic Applications Pharmacol. Rev. (IF 25.468) Pub Date : 2021-04-01 Jaclyn N. Highland, Panos Zanos, Lace M. Riggs, Polymnia Georgiou, Sarah M. Clark, Patrick J. Morris, Ruin Moaddel, Craig J. Thomas, Carlos A. Zarate, Edna F. R. Pereira, Todd D. Gould, Robert Dantzer
Hydroxynorketamines (HNKs) are formed in vivo after (R,S)-ketamine (ketamine) administration. The 12 HNK stereoisomers are distinguished by the position of cyclohexyl ring hydroxylation (at the 4, 5, or 6 position) and their unique stereochemistry at two stereocenters. Although HNKs were initially classified as inactive metabolites because of their lack of anesthetic effects, more recent studies have
-
Sex- and Gender-Based Pharmacological Response to Drugs Pharmacol. Rev. (IF 25.468) Pub Date : 2021-04-01 Franck Mauvais-Jarvis, Heiner K. Berthold, Ilaria Campesi, Juan-Jesus Carrero, Santosh Dakal, Flavia Franconi, Ioanna Gouni-Berthold, Mark L. Heiman, Alexandra Kautzky-Willer, Sabra L. Klein, Anne Murphy, Vera Regitz-Zagrosek, Karen Reue, Joshua B. Rubin, Eric Barker
In humans, the combination of all sex-specific genetic, epigenetic, and hormonal influences of biologic sex produces different in vivo environments for male and female cells. We dissect how these influences of sex modify the pharmacokinetics and pharmacodynamics of multiple drugs and provide examples for common drugs acting on specific organ systems. We also discuss how gender of physicians and patients
-
Rescuing the Last-Line Polymyxins: Achievements and Challenges Pharmacol. Rev. (IF 25.468) Pub Date : 2021-04-01 Sue C. Nang, Mohammad A. K. Azad, Tony Velkov, Qi (Tony) Zhou, Jian Li, Eric Barker
-
Ontogeny of Hepatic Transporters and Drug-Metabolizing Enzymes in Humans and in Nonclinical Species Pharmacol. Rev. (IF 25.468) Pub Date : 2021-04-01 B. D. van Groen, J. Nicolaï, A. C. Kuik, S. Van Cruchten, E. van Peer, A. Smits, S. Schmidt, S. N. de Wildt, K. Allegaert, L. De Schaepdrijver, P. Annaert, J. Badée, Hyunyoung Jeong
-
Evidence for Modulation of Substance Use Disorders by the Gut Microbiome: Hidden in Plain Sight Pharmacol. Rev. (IF 25.468) Pub Date : 2021-04-01 Mariana Angoa-Pérez, Donald M. Kuhn, Charles France
The gut microbiome modulates neurochemical function and behavior and has been implicated in numerous central nervous system (CNS) diseases, including developmental, neurodegenerative, and psychiatric disorders. Substance use disorders (SUDs) remain a serious threat to the public well-being, yet gut microbiome involvement in drug abuse has received very little attention. Studies of the mechanisms underlying
-
Correction to "Pharmacological Manipulation of Translation as a Therapeutic Target for Chronic Pain". Pharmacol. Rev. (IF 25.468) Pub Date : 2021-01-01